Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Net Margin (2016 - 2023)

Historic Net Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 31552.47%.

  • Spyre Therapeutics' Net Margin fell 279807900.0% to 31552.47% in Q2 2023 from the same period last year, while for Mar 2024 it was 52939.68%, marking a year-over-year decrease of 462614800.0%. This contributed to the annual value of 38238.15% for FY2023, which is 346393900.0% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Net Margin is 31552.47%, which was down 279807900.0% from 9304.04% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Net Margin registered a high of 56.92% during Q2 2021, and its lowest value of 31552.47% during Q2 2023.
  • For the 3-year period, Spyre Therapeutics' Net Margin averaged around 7632.49%, with its median value being 3571.68% (2022).
  • As far as peak fluctuations go, Spyre Therapeutics' Net Margin tumbled by -35147600bps in 2022, and later tumbled by -279807900bps in 2023.
  • Spyre Therapeutics' Net Margin (Quarter) stood at 561.09% in 2021, then tumbled by -1897bps to 11203.57% in 2022, then tumbled by -182bps to 31552.47% in 2023.
  • Its Net Margin was 31552.47% in Q2 2023, compared to 9304.04% in Q1 2023 and 11203.57% in Q4 2022.